Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization.

Boutin JA, Bouillaud F, Janda E, Gacsalyi I, Guillaumet G, Hirsch EC, Kane DA, Nepveu F, Reybier K, Dupuis P, Bertrand M, Chhour M, Le Diguarher T, Antoine M, Brebner K, Da Costa H, Ducrot P, Giganti A, Goswami V, Guedouari H, Michel PP, Patel A, Paysant J, Stojko J, Viaud-Massuard MC, Ferry G.

Mol Pharmacol. 2019 Mar;95(3):269-285. doi: 10.1124/mol.118.114231. Epub 2018 Dec 19.

2.

Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity.

Maatouk L, Yi C, Carrillo-de Sauvage MA, Compagnion AC, Hunot S, Ezan P, Hirsch EC, Koulakoff A, Pfrieger FW, Tronche F, Leybaert L, Giaume C, Vyas S.

Cell Death Differ. 2019 Mar;26(3):580-596. doi: 10.1038/s41418-018-0150-3. Epub 2018 Jul 13.

3.

The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons.

Lavaur J, Le Nogue D, Lemaire M, Pype J, Farjot G, Hirsch EC, Michel PP.

J Neurochem. 2017 Jul;142(1):14-28. doi: 10.1111/jnc.14041. Epub 2017 May 16.

4.

Dysfunction of mitochondrial Lon protease and identification of oxidized protein in mouse brain following exposure to MPTP: Implications for Parkinson disease.

Bulteau AL, Mena NP, Auchère F, Lee I, Prigent A, Lobsiger CS, Camadro JM, Hirsch EC.

Free Radic Biol Med. 2017 Jul;108:236-246. doi: 10.1016/j.freeradbiomed.2017.03.036. Epub 2017 Mar 30.

PMID:
28365360
5.

Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.

Parillaud VR, Lornet G, Monnet Y, Privat AL, Haddad AT, Brochard V, Bekaert A, de Chanville CB, Hirsch EC, Combadière C, Hunot S, Lobsiger CS.

J Neuroinflammation. 2017 Mar 21;14(1):60. doi: 10.1186/s12974-017-0830-9.

6.

Hepcidin attenuates amyloid beta-induced inflammatory and pro-oxidant responses in astrocytes and microglia.

Urrutia PJ, Hirsch EC, González-Billault C, Núñez MT.

J Neurochem. 2017 Jul;142(1):140-152. doi: 10.1111/jnc.14005. Epub 2017 Apr 4.

7.

Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Techniques, Side Effects, and Postoperative Imaging.

Hamani C, Lozano AM, Mazzone PA, Moro E, Hutchison W, Silburn PA, Zrinzo L, Alam M, Goetz L, Pereira E, Rughani A, Thevathasan W, Aziz T, Bloem BR, Brown P, Chabardes S, Coyne T, Foote K, Garcia-Rill E, Hirsch EC, Okun MS, Krauss JK.

Stereotact Funct Neurosurg. 2016;94(5):307-319. Epub 2016 Oct 12. Review.

8.

Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Anatomy and Terminology.

Hamani C, Aziz T, Bloem BR, Brown P, Chabardes S, Coyne T, Foote K, Garcia-Rill E, Hirsch EC, Lozano AM, Mazzone PA, Okun MS, Hutchison W, Silburn P, Zrinzo L, Alam M, Goetz L, Pereira E, Rughani A, Thevathasan W, Moro E, Krauss JK.

Stereotact Funct Neurosurg. 2016;94(5):298-306. Epub 2016 Oct 11. Review.

9.

Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress.

Lavaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP.

Cell Death Discov. 2016 May 16;2:16018. doi: 10.1038/cddiscovery.2016.18. eCollection 2016.

10.

Understanding Dopaminergic Cell Death Pathways in Parkinson Disease.

Michel PP, Hirsch EC, Hunot S.

Neuron. 2016 May 18;90(4):675-91. doi: 10.1016/j.neuron.2016.03.038. Review.

11.

Neuroprotective and neurorestorative potential of xenon.

Lavaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP.

Cell Death Dis. 2016 Apr 7;7:e2182. doi: 10.1038/cddis.2016.86. No abstract available.

12.

Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.

Bensaid M, Michel PP, Clark SD, Hirsch EC, François C.

Exp Neurol. 2016 Jan;275 Pt 1:209-19. doi: 10.1016/j.expneurol.2015.11.004. Epub 2015 Nov 10.

PMID:
26571193
13.

Piperazine derivatives as iron chelators: a potential application in neurobiology.

Abdelsayed S, Duong NT, Bureau C, Michel PP, Hirsch EC, Chahine JM, Serradji N.

Biometals. 2015 Dec;28(6):1043-61. doi: 10.1007/s10534-015-9889-x.

PMID:
26502356
14.

Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.

Belaid H, Adrien J, Karachi C, Hirsch EC, François C.

Sleep Med. 2015 Oct;16(10):1245-51. doi: 10.1016/j.sleep.2015.06.018. Epub 2015 Jul 14.

PMID:
26429753
15.

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.

Mellone M, Stanic J, Hernandez LF, Iglesias E, Zianni E, Longhi A, Prigent A, Picconi B, Calabresi P, Hirsch EC, Obeso JA, Di Luca M, Gardoni F.

Front Cell Neurosci. 2015 Jul 6;9:245. doi: 10.3389/fncel.2015.00245. eCollection 2015.

16.

Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.

Noelker C, Lu L, Höllerhage M, Vulinovic F, Sturn A, Roscher R, Höglinger GU, Hirsch EC, Oertel WH, Alvarez-Fischer D, Andreas H.

J Neurol Sci. 2015 Sep 15;356(1-2):129-36. doi: 10.1016/j.jns.2015.06.030. Epub 2015 Jun 17.

PMID:
26104567
17.

In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.

Féger J, Hirsch EC.

Ann Pharm Fr. 2015 Jan;73(1):3-12. doi: 10.1016/j.pharma.2014.10.001. Epub 2014 Nov 4. Review.

PMID:
25577012
18.

The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine.

Guerreiro S, Florence C, Rousseau E, Hamadat S, Hirsch EC, Michel PP.

Mol Pharmacol. 2015;87(3):525-32. doi: 10.1124/mol.114.095703. Epub 2014 Dec 31.

PMID:
25552485
19.

The global fight against dementia.

Joanette Y, Hirsch EC, Goldman M.

Sci Transl Med. 2014 Dec 17;6(267):267ed22. doi: 10.1126/scitranslmed.aaa4486. No abstract available.

20.

Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.

Bensaid M, Tandé D, Fabre V, Michel PP, Hirsch EC, François C.

Eur J Neurosci. 2015 Jan;41(1):129-36. doi: 10.1111/ejn.12761. Epub 2014 Oct 18.

PMID:
25328140
21.

Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.

Belaid H, Adrien J, Laffrat E, Tandé D, Karachi C, Grabli D, Arnulf I, Clark SD, Drouot X, Hirsch EC, François C.

J Neurosci. 2014 Jul 2;34(27):9124-33. doi: 10.1523/JNEUROSCI.0181-14.2014.

22.

Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.

Noelker C, Morel L, Osterloh A, Alvarez-Fischer D, Lescot T, Breloer M, Gold M, Oertel WH, Henze C, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A.

J Neuroinflammation. 2014 May 8;11:86. doi: 10.1186/1742-2094-11-86.

23.

The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis.

Rousseau E, Michel PP, Hirsch EC.

Mol Pharmacol. 2013 Dec;84(6):888-98. doi: 10.1124/mol.113.087965. Epub 2013 Sep 27.

PMID:
24077968
24.

Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems.

Grabli D, Karachi C, Folgoas E, Monfort M, Tande D, Clark S, Civelli O, Hirsch EC, François C.

J Neurosci. 2013 Jul 17;33(29):11986-93. doi: 10.1523/JNEUROSCI.1568-13.2013.

25.

DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease.

Kinugawa K, Monnet Y, Béchade C, Alvarez-Fischer D, Hirsch EC, Bessis A, Hunot S.

J Neuroinflammation. 2013 Jul 11;10:82. doi: 10.1186/1742-2094-10-82.

26.

[Future drug targets for Parkinson's disease].

Hirsch EC.

Bull Acad Natl Med. 2012 Oct;196(7):1369-77; discussion 1377-9. Review. French.

27.

Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.

Alvarez-Fischer D, Noelker C, Grünewald A, Vulinović F, Guerreiro S, Fuchs J, Lu L, Lombès A, Hirsch EC, Oertel WH, Michel PP, Hartmann A.

J Neurochem. 2013 Dec;127(6):782-92. doi: 10.1111/jnc.12343. Epub 2013 Jul 8.

28.

Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease.

Michel PP, Toulorge D, Guerreiro S, Hirsch EC.

FASEB J. 2013 Sep;27(9):3414-23. doi: 10.1096/fj.12-220418. Epub 2013 May 22. Review.

PMID:
23699175
29.

Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model.

Alvarez-Fischer D, Noelker C, Vulinović F, Grünewald A, Chevarin C, Klein C, Oertel WH, Hirsch EC, Michel PP, Hartmann A.

PLoS One. 2013 Apr 18;8(4):e61700. doi: 10.1371/journal.pone.0061700. Print 2013.

30.

Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease.

Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A.

Sci Rep. 2013;3:1393. doi: 10.1038/srep01393.

31.

MFGE8 does not orchestrate clearance of apoptotic neurons in a mouse model of Parkinson's disease.

Kinugawa K, Monnet Y, Lu L, Bekaert AJ, Théry C, Mallat Z, Hirsch EC, Hunot S.

Neurobiol Dis. 2013 Mar;51:192-201. doi: 10.1016/j.nbd.2012.11.010. Epub 2012 Nov 27.

PMID:
23194669
32.

Flavaglines as potent anticancer and cytoprotective agents.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Désaubry L.

J Med Chem. 2012 Nov 26;55(22):10064-73. doi: 10.1021/jm301201z. Epub 2012 Oct 23.

PMID:
23072299
33.

Pathogenesis of Parkinson's disease.

Hirsch EC, Jenner P, Przedborski S.

Mov Disord. 2013 Jan;28(1):24-30. doi: 10.1002/mds.25032. Epub 2012 Aug 23. Review.

PMID:
22927094
34.

Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-α/epidermal growth factor receptor signaling pathway.

Rousselet E, Traver S, Monnet Y, Perrin A, Mandjee N, Hild A, Hirsch EC, Zheng TS, Hunot S.

Mol Pharmacol. 2012 Nov;82(5):948-57. doi: 10.1124/mol.112.079608. Epub 2012 Aug 21.

PMID:
22909796
35.

Normal and pathological gait: what we learn from Parkinson's disease.

Grabli D, Karachi C, Welter ML, Lau B, Hirsch EC, Vidailhet M, François C.

J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):979-85. doi: 10.1136/jnnp-2012-302263. Epub 2012 Jun 29. Review.

36.

Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Schumm S, Sebban C, Cohen-Salmon C, Callebert J, Launay JM, Golmard JL, Boussicault L, Petropoulos I, Hild A, Rousselet E, Prigent A, Friguet B, Mariani J, Hirsch EC.

J Neurochem. 2012 Sep;122(5):1032-46. doi: 10.1111/j.1471-4159.2012.07837.x. Epub 2012 Jul 11.

37.

Quantitative evaluation of the human subventricular zone.

Höglinger GU, Barker RA, Hagg T, Arias-Carrión O, Caldwell MA, Hirsch EC.

Brain. 2012 Aug;135(Pt 8):e221, 1-4; author reply e222, 1-6. doi: 10.1093/brain/aws087. Epub 2012 Apr 25. No abstract available.

PMID:
22539257
38.

Neuroinflammation in Parkinson's disease.

Hirsch EC, Vyas S, Hunot S.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2. doi: 10.1016/S1353-8020(11)70065-7. Review.

PMID:
22166438
39.

Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity.

Mena NP, Bulteau AL, Salazar J, Hirsch EC, Núñez MT.

Biochem Biophys Res Commun. 2011 Jun 3;409(2):241-6. doi: 10.1016/j.bbrc.2011.04.137. Epub 2011 May 6.

PMID:
21570952
40.

Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.

Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP.

FASEB J. 2011 Aug;25(8):2563-73. doi: 10.1096/fj.11-182824. Epub 2011 Apr 20.

PMID:
21507900
41.

Internal pallidum and substantia nigra control different parts of the mesopontine reticular formation in primate.

Rolland AS, Karachi C, Muriel MP, Hirsch EC, François C.

Mov Disord. 2011 Aug 1;26(9):1648-56. doi: 10.1002/mds.23705. Epub 2011 Apr 5.

PMID:
21469212
42.

Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism.

Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6632-7. doi: 10.1073/pnas.1017820108. Epub 2011 Apr 5.

43.

Pathophysiological involvement of neuroinflammation in various neurological disorders.

Hirsch EC, Hunot S.

J Neural Transm (Vienna). 2010 Aug;117(8):897-8. doi: 10.1007/s00702-010-0439-y. Epub 2010 Jul 27. No abstract available.

PMID:
20661757
44.

Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease.

Karachi C, Grabli D, Bernard FA, Tandé D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker HP, Hunot S, Hartmann A, Lehéricy S, Hirsch EC, François C.

J Clin Invest. 2010 Aug;120(8):2745-54. doi: 10.1172/JCI42642. Epub 2010 Jul 12.

45.

Missing pieces in the Parkinson's disease puzzle.

Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G.

Nat Med. 2010 Jun;16(6):653-61. doi: 10.1038/nm.2165. Epub 2010 May 23. Review.

PMID:
20495568
46.

KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis.

Toulorge D, Guerreiro S, Hirsch EC, Michel PP.

J Neurochem. 2010 Jul;114(2):553-64. doi: 10.1111/j.1471-4159.2010.06785.x. Epub 2010 Apr 29.

47.

Iron transport in Parkinson's disease.

Hirsch EC.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S209-11. doi: 10.1016/S1353-8020(09)70816-8.

PMID:
20082992
48.

Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.

Rolland AS, Tandé D, Herrero MT, Luquin MR, Vazquez-Claverie M, Karachi C, Hirsch EC, François C.

J Neurochem. 2009 Aug;110(4):1321-9. doi: 10.1111/j.1471-4159.2009.06220.x. Epub 2009 Jun 12.

49.

Dysfunction of the subthalamic nucleus induces behavioral and movement disorders in monkeys.

Karachi C, Grabli D, Baup N, Mounayar S, Tandé D, François C, Hirsch EC.

Mov Disord. 2009 Jun 15;24(8):1183-92. doi: 10.1002/mds.22547.

PMID:
19412950
50.

Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization.

Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, Michel PP.

J Neurochem. 2009 May;109(4):1118-28. doi: 10.1111/j.1471-4159.2009.06040.x. Epub 2009 Mar 19.

Supplemental Content

Loading ...
Support Center